The device delivers conduction pacing to the heart's left bundle branch area by mimicking the heart's electrical rhythm, the company said.

Abbott also recently started enrolling patients in a clinical trial of up to 414 people to evaluate the safety and effectiveness of its investigational CSP Implantable Cardioverter-Defibrillator lead.

The US Food and Drug Administration recently granted breakthrough device designations to both the Aveir and CSP devices, the company said.

http://www.mtnewswires.com
Copyright © 2025 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.